Julio Rosenstock
Endocrinology — Medical City Dallas Hospital, United States
Julio Rosenstock
LeadR Profile
Endocrinology
Subspecialties: Cardiology - Nephrology - Gastroenterology
Main Topics
Publications and Clinical Studies
Profile data updated on
Expert Rankings
Top experts on the MeSH terms this expert works on
Organizations
Career arc: 1994 - 2026
Number : 579
Citations
Best Journals
Breakdown by type
Click a legend label to hide or show it in the chart.
Latest Publications
5 most recent indexed articles
Source: Pubmed
| Title | Journal | Year | Citations |
|---|---|---|---|
| Effect of Semaglutide on Thigh Skeletal Muscle Volume, Fat Infiltration and Physical Function in People With Obesity: Secondary Analysis of STEP UP. muscles, anti-obesity agents, body composition, obesity, muscle, skeletal, tissues, adipose tissue, weight control, semaglutide | Diabetes Obes Metab | 2026 | 0 |
| Racial outcomes in patients with diabetic cardiomyopathy treated with an aldose reductase inhibitor: the ARISE-HF trial. aldehyde reductase, oxidoreductases, diabetic cardiomyopathies, cardiovascular diseases, disease progression, cardiomyopathies | Open Heart | 2026 | 0 |
| Efficacy and safety of once-weekly subcutaneous zenagamtide, a novel unimolecular GLP-1 and amylin receptor agonist, in type 2 diabetes: a multicentre, randomised, parallel, double-blind, placebo-controlled, dose-finding, phase 2 trial. diabetes mellitus, glucagon-like peptide 1, receptors, islet amyloid polypeptide, safety, amylin receptor agonists, drug-related side effects and adverse reactions, therapeutics, islet amyloid polypeptide, diabetes mellitus, type 2 | Lancet Top journal | 2026 | 2 |
| Efficacy and safety of once-daily oral zenagamtide, a novel unimolecular GLP-1 and amylin receptor agonist, in adults with type 2 diabetes: a multicentre, randomised, parallel, double-blind, placebo-controlled, dose-finding, phase 2 trial. diabetes mellitus, glucagon-like peptide 1, receptors, islet amyloid polypeptide, safety, amylin receptor agonists, drug-related side effects and adverse reactions, therapeutics, islet amyloid polypeptide, diabetes mellitus, type 2 | Lancet Top journal | 2026 | 2 |
| Oral GLP-1RA TERN-601 for Adults With Obesity/Overweight: Placebo-Controlled, Multiple-Ascending-Dose, Phase 1 and 2 Studies. glucagon-like peptide 1, safety, gastric emptying, liver, appetite, obesity, weight loss, overweight, pharmacokinetics | Obesity (Silver Spring) | 2026 | 0 |
Clinical Studies 154
Synthesis
By phase:
By status:
By type:
By Monocentric/Multicentric:
Cohort/Consortium Investigators 1
Ongoing Clinical Trials
4 ongoing trials started since 2021, where this expert is an investigator
Source: ClinicalTrials
| Study | Phase | Status | Start |
|---|---|---|---|
| A Phase 3 Study to Evaluate the Efficacy and Safety of ORMD 0801 in Subjects with Type 2 Diabetes Mellitus NCT06731075 — diabetes mellitus, safety, insulin, multiple chronic conditions, capsules, glycemic control, diabetes mellitus, type 2 | Phase 3 | Not yet recruiting | 2025 |
| Study to Determine the Prevalence of Hypercortisolism in Patients With Type 2 Diabetes and Treatment With Korlym (Mifepristone) (CATALYST) NCT05772169 — diabetes mellitus, tablets, prevalence, therapeutics, mifepristone, adrenocortical hyperfunction, cushing syndrome, diabetes mellitus, type 2 | Phase 4 | Recruiting | 2023 |
| A Research Study to See How Well CagriSema Helps People With Excess Body Weight Lose Weight NCT05567796 — safety, body weight, obesity, research, overweight, semaglutide | Phase 3 | Active not recruiting | 2022 |
| Research Study on Whether Semaglutide Works in People With Non alcoholic Steatohepatitis (NASH) NCT04822181 — liver diseases, skin, non-alcoholic fatty liver disease, liver, alcoholics, research, fatty liver, fatty liver, alcoholic, semaglutide | Phase 3 | Active not recruiting | 2021 |
LeadR Networks
Main global connection map